CRNX - Crinetics reports encouraging Phase 2 data for carcinoid syndrome drug
2024-03-12 17:04:09 ET
More on Crinetics Pharmaceuticals
- Crinetics: Paltusotine's Phase 3 Triumph Transforms Trajectory (Rating Upgrade)
- Crinetics Pharmaceuticals, Inc. (CRNX) Q4 2023 Earnings Call Transcript
- Citi starts Crinetics at buy, cites upcoming data for lead drug
- Seeking Alpha’s Quant Rating on Crinetics Pharmaceuticals
- Historical earnings data for Crinetics Pharmaceuticals